Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study

Gastroenterology

Volumn 153, Issue 1, 2017, Pages 77-86.e6

  Sands, Bruce E ^a   Chen, Jingjing ^b   Feagan, Brian G ^c   Penney, Mark ^d   Rees, William A ^b   Danese, Silvio ^e   Higgins, Peter D R ^f   Newbold, Paul ^b   Faggioni, Raffaella ^b   Patra, Kaushik ^b   Li, Jing ^b   Klekotka, Paul ^g   Morehouse, Chris ^b   Pulkstenis, Erik ^b   Drappa, Jörn ^b   van der Merwe, René ^d   Gasser, Robert A ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MEDIMMUNE   (United States)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d MEDIMMUNE LTD   (United Kingdom)

^e HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^f UNIVERSITY OF MICHIGAN   (United States)

^g AMGEN INC   (United States)

Author keywords

Clinical Trial; IL22; IL23; Phase II

Indexed keywords

BIOLOGICAL MARKER; BRAZIKUMAB; C REACTIVE PROTEIN; CALGRANULIN; DRUG ANTIBODY; INTERLEUKIN 22; INTERLEUKIN 23; PLACEBO; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22; MONOCLONAL ANTIBODY;

ABDOMINAL ABSCESS; ABDOMINAL PAIN; ADULT; ANEMIA; ARTHRALGIA; ARTICLE; BLOOD LEVEL; BRONCHITIS; CELLULITIS; CLINICAL OUTCOME; CLOSTRIDIUM DIFFICILE INFECTION; COLON PERFORATION; CONTROLLED STUDY; COUGHING; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DIARRHEA; DISEASE ACTIVITY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; GASTROENTERITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL INFECTION; HEADACHE; HUMAN; IMMUNOGENICITY; INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; NAUSEA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROCTALGIA; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SKIN ABSCESS; SWEAT GLAND DISEASE; SWEAT GLAND INFECTION; TOOTH ABSCESS; TRACHEOBRONCHITIS; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; VOMITING; VULVOVAGINAL DISEASE; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; MIDDLE AGED; RETREATMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DOUBLE-BLIND METHOD; FEMALE; HEADACHE; HUMANS; INTERLEUKIN-23; INTERLEUKINS; MALE; MIDDLE AGED; NASOPHARYNGITIS; RETREATMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85020929772     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2017.03.049     Document Type: Article

References (25)

1. Baumgart, D.C., Sandborn, W.J., Crohn's disease. Lancet 380 (2012), 1590–1605.
2. Colombel, J.F., Sandborn, W.J., Rutgeerts, P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132 (2007), 52–65.
3. Hanauer, S.B., Feagan, B.G., Lichtenstein, G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002), 1541–1549.
4. Hanauer, S.B., Sandborn, W.J., Rutgeerts, P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130 (2006), 323–333.
5. Schreiber, S., Khaliq-Kareemi, M., Lawrance, I.C., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 357 (2007), 239–250.
6. Targan, S.R., Hanauer, S.B., van Deventer, S.J., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337 (1997), 1029–1035.
7. Sandborn, W.J., Colombel, J.F., Schreiber, S., et al. Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis 17 (2011), 141–151.
8. Rutgeerts, P., Feagan, B.G., Lichtenstein, G.R., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126 (2004), 402–413.
9. Sandborn, W.J., Rutgeerts, P., Enns, R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146 (2007), 829–838.
10. Sandborn, W.J., Feagan, B.G., Stoinov, S., et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357 (2007), 228–238.
11. Ahern, P.P., Izcue, A., Maloy, K.J., Powrie, F., The interleukin-23 axis in intestinal inflammation. Immunol Rev 226 (2008), 147–159.
12. Cayatte, C., Joyce-Shaikh, B., Vega, F., et al. Biomarkers of therapeutic response in the IL-23 pathway in inflammatory bowel disease. Clin Transl Gastroenterol, 3, 2012, e10.
13. Oppmann, B., Lesley, R., Blom, B., et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13 (2000), 715–725.
14. Andoh, A., Zhang, Z., Inatomi, O., et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 129 (2005), 969–984.
15. Brand, S., Dambacher, J., Beigel, F., et al. IL-22-mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro. Am J Physiol Gastrointest Liver Physiol 292 (2007), G1019–G1028.
16. Schmechel, S., Konrad, A., Diegelmann, J., et al. Linking genetic susceptibility to Crohn's disease with Th17 cell function: IL-22 serum levels are increased in Crohn's disease and correlate with disease activity and IL23R genotype status. Inflamm Bowel Dis 14 (2008), 204–212.
17. Jostins, L., Ripke, S., Weersma, R.K., et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491 (2012), 119–124.
18. Kobayashi, T., Okamoto, S., Hisamatsu, T., et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut 57 (2008), 1682–1689.
19. Schmidt, C., Giese, T., Ludwig, B., et al. Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm Bowel Dis 11 (2005), 16–23.
20. Sandborn, W.J., Gasink, C., Gao, L.L., et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 367 (2012), 1519–1528.
21. Kock, K., Pan, W.J., Gow, J.M., et al. Preclinical development of AMG 139, a human antibody specifically targeting IL-23. Br J Pharmacol 172 (2015), 159–172.
22. Best, W.R., Becktel, J.M., Singleton, J.W., Kern, F. Jr., Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70 (1976), 439–444.
23. Faubion, W.A. Jr., Fletcher, J.G., O'Byrne, S., et al. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging. Am J Gastroenterol 108 (2013), 1891–1900.
24. Ge, M., Durham, L.K., Meyer, R.D., Wangang, X., Thomas, N., Covariate-adjusted difference in proportions from clinical trials using logistic regression and weighted risk differences. Drug Inf J 45 (2011), 481–493.
25. Dige, A., Stoy, S., Rasmussen, T.K., et al. Increased levels of circulating Th17 cells in quiescent versus active Crohn's disease. J Crohns Colitis 7 (2013), 248–255.